-
Jul 29, 2024 | 
medrxiv.org | Mary McGowan |Chao Xing |Amit V. Khera |Chun-Yuan Huang
ZA research funding from US Department of Defense, National Institute of Health, and Ionis Pharmaceuticals; Site Primary Investigator for Ionis Pharmaceuticals. AK: research funding from National Institute of HealthnoneI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
-
Mar 12, 2024 | 
healio.com | Erik Swain |Mary McGowan
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The FDA extended its approval of alirocumab to treat a genetic lipid disorder in patients as young as 8 years. Approval was based on a recent phase 3 trial.
-
Feb 22, 2024 | 
beckershospitalreview.com | Mary McGowan
Heart disease remains the number 1 cause of death among individuals worldwide. To reduce this threat, a variety of screenings are used to monitor heart health, including blood tests to check levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and a blood fat called triglycerides. Screening patients in this way can identify people at risk for heart disease and help reduce that risk through lifestyle and when necessary, medications.
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: I’m going to give each of you about a minute or so to give what we call a take-home message: a clinical pearl for the physicians, nurse practitioners, physician assistants, [and] pharmacists who may be listening, something that will motivate them to do better. We’ve heard from the Family Heart Foundation that we’re not recognizing these patients early enough and that those patients at high risk are not getting high-intensity statin.
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: Christie, where are we going with lipoprotein(a) [Lp(a)]? Have we reached the end of the road, or is there something on the horizon? Christie M. Ballantyne, MD, FACC: We’re just moving, and I agree with my colleagues. I screen everybody in my personal practice. I also do cascade screening. One thing we didn’t mention but I think is very important is if you’re looking at Black individuals, [they have] the highest levels of Lp(a), and it is a risk factor.
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: Dr [Payal] Kohli[, MD, FACC], the PCSK9 inhibitors were [addressed], and I know you’ve looked at some of the more recent data. They’ve been around a long time, and we now have data that [show] they really do work, and…for a long period…. Do you want to discuss that? Payal Kohli, MD, FACC: That’s right.
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: We’re going to switch gears [and] go to an LDL [low-density lipoprotein]–like biomarker; it’s a substance that’s a causal agent for atherosclerotic cardiovascular disease, [and] that’s lipoprotein a [Lp(a)]. Now FH is not just familial hypercholesterolemia. The [Family Heart] Foundation also embraces putting more attention on lipoprotein a…. Dr [Mary] McGowan[, MD, FNLA], you want to tell us about Lp(a)? Mary McGowan, MD, FNLA: Sure.
-
Nov 27, 2023 | 
consultantlive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
New Guidance, New Data and New Targets for the Management of Hyperlipidemia - Episode 11Published on: , , , , Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor. Keith C. Ferdinand, MD, FACC, FAHA, FNLA: Dr [Payal] Kohli[, MD, FACC], the PCSK9 inhibitors were [addressed], and I know you’ve looked at some of the more recent data.
-
Oct 5, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: Dr Ballantyne, I’m a hypertension specialist. We start combination therapy in most middle-aged and older patients, especially higher risk patients. I think I’ve heard you speak about combining different medications from different classes. Do you want to address that? Christie M. Ballantyne, MD, FACC: When I first trained, I was in Dallas, [Texas], and we had Norman Kaplan, [MD]. He’s a hypertension guru.
-
Oct 5, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: I think we can all agree that if a patient really cannot tolerate a statin, perhaps we can address their lipids using other nonstatin therapies. That leads me to you, Dr Michos. Can you give us a laundry list—it doesn’t have to be totally comprehensive—but [a list of] some of the newer agents that we have or alternative agents for statins in order to treat these patients who have elevated lipids? Erin D. Michos, MD, MHS: Sure.
